Tetra Bio-Pharma Adds New Marketing Vice-President
August 30 2018 - 8:00AM
Tetra Bio-Pharma Inc., a leader in
cannabinoid-based drug discovery and development (TSX VENTURE: TBP)
(OTCQB: TBPMF), is pleased to announce that Mr. Steeve
Neron has joined Tetra Bio-Pharma as Vice-President,
Marketing, effective August 20, 2018. He will be responsible for
all Tetra Bio-Pharma and Tetra Natural Heath marketing activities.
Steeve has more than 32 years’ experience
in the pharmaceutical industry with demonstrated success in
numerous therapeutic sectors including cardiology, rheumatology,
endocrinology, women’s health, asthma/COPD, OTC and dermatology
where challenging the reimbursement landscape factored prominently
in his role. Prior to joining Tetra Bio-Pharma he occupied a senior
marketing position at Bausch Health Canada, formerly Valeant.
Steeve has held various marketing, sales,
finance, material management and business development positions and
has worked to launch or rejuvenate numerous market leading
pharmaceutical brands including Aerius™ (antihistamine), Altace™
(hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant),
Lodalis™ (cholesterol) and Contrave™ (Obesity).
“I am very proud to add Steeve to our
senior management team. His vast experience will enable Tetra to
achieve its high standards in executional excellence,”
says Richard Giguere Executive Vice-President, Commercial
Operations.
“I am very excited to have the opportunity of
contributing my pharmaceutical marketing knowledge within the
growing cannabinoid-based products sector,” said Steeve Neron.
“Tetra has set the bar high from a clinical development standpoint
and this is a critical factor to maximize the therapeutic potential
of cannabis.”
About Tetra
Bio-PharmaTetra Bio-Pharma (TSX-V: TBP) (OTCQB:
TBPMF) is a biopharmaceutical leader in cannabinoid-based drug
discovery and development with a Health Canada approved,
and FDA reviewed, clinical program aimed at bringing
novel prescription drugs and treatments to patients and their
healthcare providers. The Company has several subsidiaries engaged
in the development of an advanced and growing pipeline of Bio
Pharmaceuticals, Natural Health and Veterinary Products
containing cannabis and other medicinal plant-based elements. With
patients at the core of what we do, Tetra Bio-Pharma is
focused on providing rigorous scientific validation and safety data
required for inclusion into the existing bio pharma industry by
regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-looking statementsSome
statements in this release may contain forward-looking information.
All statements, other than of historical fact, that address
activities, events or developments that the Company believes,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words "may",
"will", "should", "continue", "expect", "anticipate", "estimate",
"believe", "intend", "plan" or "project" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the ability to
obtain orphan drug status, the applicability of the discoveries
made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. While no definitive documentation has yet been signed
by the parties and there is no certainty that such documentation
will be signed. The forward-looking statements included in this
news release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
For further information, please contact Tetra Bio-Pharma
Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514 Investors@tetrabiopharma.com
Media Contact energi PR Carol Levine
Carol.Levine@energipr.com 514-288-8500 ext. 225 416-425-9143 ext.
225
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Sep 2023 to Sep 2024